WAT Stock Analysis — Waters Corporation
Sector: Healthcare
AI Verdict
Waters trades at 26.2x next year's earnings with sky-high growth baked in, so you’re paying up for a turnaround story that only holds if their sticky lab instrument moat delivers on the forecast.
Competitive Moat
Waters specializes in high-precision liquid chromatography and mass spectrometry instruments, which are mission-critical for pharmaceutical and life science labs. Its moat comes from deep integration into customer workflows and high switching costs due to proprietary hardware, software, and support ecosystems.
Summary
A huge 292.5% jump in expected earnings has reset the narrative for this lab instrument maker.
Where It Stands
With a 1-year return of 40.19%, an RSI of 77.9 (overbought), and a forward P/E of 26.2x versus the healthcare sector median of 22x, the stock is riding high on optimism.
Key Metrics
- RSI: 77.9 — Overbought
- Trailing P/E: 102.8x
- Forward P/E: 26.2x
- PEG Ratio: 0.35
- Earnings Growth: +2.9%
- Revenue Growth: +0.5%
- Market Cap: $40.4B
- 1-Year Return: 40.19%
- 52-Week High: $420.26
- 52-Week Low: $282.77
Analyst Consensus
17 Buy · 14 Hold · 0 Sell (31 analysts)
Bull Case
Forward EPS growth of 292.5% means you’re paying 26.2x next year’s earnings for a business that just grew revenue 52.5% year-over-year.
Bear Case
An RSI of 77.9 signals overbought territory, so even a modest pullback to a neutral RSI could mean a 10–15% drop from these levels if sentiment cools.
Catalyst to Watch
Watch for quarterly earnings to confirm the massive EPS growth — any miss could trigger a sharp valuation reset.